These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 35790190)

  • 21. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
    Liu L; Iketani S; Guo Y; Chan JF; Wang M; Liu L; Luo Y; Chu H; Huang Y; Nair MS; Yu J; Chik KK; Yuen TT; Yoon C; To KK; Chen H; Yin MT; Sobieszczyk ME; Huang Y; Wang HH; Sheng Z; Yuen KY; Ho DD
    Nature; 2022 Feb; 602(7898):676-681. PubMed ID: 35016198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
    Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
    Yang S; Yu Y; Jian F; Yisimayi A; Song W; Liu J; Wang P; Xu Y; Wang J; Niu X; Yu L; Wang Y; Shao F; Jin R; Wang Y; Cao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2343909. PubMed ID: 38616729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants.
    Moriyama S; Anraku Y; Taminishi S; Adachi Y; Kuroda D; Kita S; Higuchi Y; Kirita Y; Kotaki R; Tonouchi K; Yumoto K; Suzuki T; Someya T; Fukuhara H; Kuroda Y; Yamamoto T; Onodera T; Fukushi S; Maeda K; Nakamura-Uchiyama F; Hashiguchi T; Hoshino A; Maenaka K; Takahashi Y
    Nat Commun; 2023 Jul; 14(1):4198. PubMed ID: 37452031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
    Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
    Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.
    Li L; Shi K; Gu Y; Xu Z; Shu C; Li D; Sun J; Cong M; Li X; Zhao X; Yu G; Hu S; Tan H; Qi J; Ma X; Liu K; Gao GF
    Structure; 2024 Aug; 32(8):1055-1067.e6. PubMed ID: 39013463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
    Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
    Bowen JE; Addetia A; Dang HV; Stewart C; Brown JT; Sharkey WK; Sprouse KR; Walls AC; Mazzitelli IG; Logue JK; Franko NM; Czudnochowski N; Powell AE; Dellota E; Ahmed K; Ansari AS; Cameroni E; Gori A; Bandera A; Posavad CM; Dan JM; Zhang Z; Weiskopf D; Sette A; Crotty S; Iqbal NT; Corti D; Geffner J; Snell G; Grifantini R; Chu HY; Veesler D
    Science; 2022 Aug; 377(6608):890-894. PubMed ID: 35857529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
    Pastorio C; Zech F; Noettger S; Jung C; Jacob T; Sanderson T; Sparrer KMJ; Kirchhoff F
    Cell Host Microbe; 2022 Sep; 30(9):1255-1268.e5. PubMed ID: 35931073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
    Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.
    Wang K; Jia Z; Bao L; Wang L; Cao L; Chi H; Hu Y; Li Q; Zhou Y; Jiang Y; Zhu Q; Deng Y; Liu P; Wang N; Wang L; Liu M; Li Y; Zhu B; Fan K; Fu W; Yang P; Pei X; Cui Z; Qin L; Ge P; Wu J; Liu S; Chen Y; Huang W; Wang Q; Qin CF; Wang Y; Qin C; Wang X
    Nature; 2022 Mar; 603(7903):919-925. PubMed ID: 35090164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omicron neutralization character in patients with breast cancer and liver cancer after the nationwide omicron outbreak.
    Zhang S; Tang L; Bao C; Wang S; Li B; Huang L; Song H; Fu J; Xu Z; Meng F; Cao L; Gao Y; Yuan Y; Chen Y; Yuan J; Zhou C; Li F; Qin L; Guo Y; Zhang C; Song J; Fan X; Jiang Z; Wang FS; Xu R
    Cancer Med; 2024 Jun; 13(11):e7304. PubMed ID: 38826094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.
    Mühlemann B; Trimpert J; Walper F; Schmidt ML; Jansen J; Schroeder S; Jeworowski LM; Beheim-Schwarzbach J; Bleicker T; Niemeyer D; Richter A; Adler JM; Vidal RM; Langner C; Vladimirova D; Wilks SH; Smith DJ; Voß M; Paltzow L; Martínez Christophersen C; Rose R; Krumbholz A; Jones TC; Corman VM; Drosten C
    Proc Natl Acad Sci U S A; 2024 Aug; 121(32):e2310917121. PubMed ID: 39078681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants.
    Ong CP; Ye ZW; Tang K; Liang R; Xie Y; Zhang H; Qin Z; Sun H; Wang TY; Cheng Y; Chu H; Chan JF; Jin DY; Yuan S
    J Med Virol; 2023 Jan; 95(1):e28326. PubMed ID: 36411262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.